Literature DB >> 29032371

Reassessing the significance of the PAH c.158G>A (p.Arg53His) variant in patients with hyperphenylalaninemia.

Rihwa Choi1, Jeongho Lee1, Hyung-Doo Park1, Jong Eun Park1, Yong Hyuk Kim1, Chang-Seok Ki1, Soo-Youn Lee1, Junghan Song1, Jong-Won Kim1, Dong Hwan Lee1.   

Abstract

BACKGROUND: The accurate interpretation of sequence variation is critical for successful molecular diagnoses. It is also fundamental to the accurate diagnosis and treatment of phenylketonuria (PKU). This study aims to evaluate the significance of the c.158G>A (p.Arg53His) variant in the PAH gene, which was previously reported to be a pathogenic mutation that results in decreased phenylalanine hydroxylase enzyme activity in hyperphenylalaninemia (HPA) patients.
METHODS: Seven unrelated Korean patients with HPA genotyped with the c.158G>A variant were included in this study. The variant c.158G>A was classified by the standards and guidelines for the interpretation of sequence variants by the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.
RESULTS: By both directly collecting genetic data and comprehensively reviewing the existing literature, we found that this variant is more appropriately classified as "Likely benign" rather than pathogenic. The allele's frequency is 2.57% in the general Korean population, which was greater than expected for phenylketonuria. This variant was observed to be homozygous in healthy subjects and was also observed in cis with other pathogenic variants. It is common in East Asian populations (especially in Koreans) compared to Western populations. There is a possibility that it causes decreased enzyme activity without leading to the full pathology of phenylketonuria.
CONCLUSIONS: This study expands our understanding of the consequences of variation in PAH and its relationship to HPA.

Entities:  

Keywords:  PAH; hyperphenylalaninemia; phenylalanine; phenylketonuria

Mesh:

Substances:

Year:  2017        PMID: 29032371     DOI: 10.1515/jpem-2017-0158

Source DB:  PubMed          Journal:  J Pediatr Endocrinol Metab        ISSN: 0334-018X            Impact factor:   1.634


  6 in total

1.  Follow-up of two newborns with c.158G>A (p.Arg53His) mutation in gene and assessment of the site function.

Authors:  Jie Wang; Bo Zhu; Lichun Zhang; Yitong Zhao; Xiaohua Wang; Yueqi Jia
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2021-08-25

2.  Neonatal screening and genotype-phenotype correlation of hyperphenylalaninemia in the Chinese population.

Authors:  Xin Wang; Yanyun Wang; Dingyuan Ma; Zhilei Zhang; Yahong Li; Peiying Yang; Yun Sun; Tao Jiang
Journal:  Orphanet J Rare Dis       Date:  2021-05-12       Impact factor: 4.123

3.  A capillary electrophoresis-based multiplex PCR assay for expanded carrier screening in the eastern Han Chinese population.

Authors:  Ping Hu; Jianxin Tan; Feng Yu; Binbin Shao; Fang Zhang; Jingjing Zhang; Yingchun Lin; Tao Tao; Lili Jiang; Zhengwen Jiang; Zhengfeng Xu
Journal:  NPJ Genom Med       Date:  2022-01-25       Impact factor: 8.617

4.  Application of a next-generation sequencing (NGS) panel in newborn screening efficiently identifies inborn disorders of neonates.

Authors:  Xinwen Huang; Dingwen Wu; Lin Zhu; Wenjun Wang; Rulai Yang; Jianbin Yang; Qunyan He; Bingquan Zhu; Ying You; Rui Xiao; Zhengyan Zhao
Journal:  Orphanet J Rare Dis       Date:  2022-02-21       Impact factor: 4.123

5.  Mutational and phenotypic spectrum of phenylalanine hydroxylase deficiency in Zhejiang Province, China.

Authors:  Ting Chen; Weize Xu; Dingwen Wu; Jiamin Han; Ling Zhu; Fan Tong; Rulai Yang; Zhengyan Zhao; Pingping Jiang; Qiang Shu
Journal:  Sci Rep       Date:  2018-11-20       Impact factor: 4.379

6.  Clinical Implementation of Expanded Carrier Screening in Pregnant Women at Early Gestational Weeks: A Chinese Cohort Study.

Authors:  Mengmeng Shi; Angeline Linna Liauw; Steve Tong; Yu Zheng; Tak Yeung Leung; Shuk Ching Chong; Ye Cao; Tze Kin Lau; Kwong Wai Choy; Jacqueline P W Chung
Journal:  Genes (Basel)       Date:  2021-03-29       Impact factor: 4.096

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.